Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 591 to 600 of 1443 total matches.
Brexpiprazole (Rexulti) for Schizophrenia and Depression
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015 (Issue 1475)
+/– +/– – ++ +
*Limited experience
117
The Medical Letter ® Vol. 57 (1475) August 17, 2015
brexpiprazole 2 mg/day than ...
The FDA has approved the oral, once-daily, second-generation
antipsychotic brexpiprazole (Rexulti –
Otsuka/Lundbeck) for treatment of schizophrenia
and as an adjunct to antidepressants for treatment
of major depressive disorder (MDD). Aripiprazole
(Abilify), a structurally similar second-generation
antipsychotic also comarketed by Otsuka (with BMS),
recently became available generically.
Palbociclib (Ibrance) for Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015 (Issue 1475)
months).5
116
The Medical Letter ® Vol. 57 (1475) August 17, 2015
counts should be monitored before ...
Palbociclib (Ibrance – Pfizer), an oral cyclin-dependent
kinase inhibitor, has been approved by the FDA for use
in combination with the aromatase inhibitor letrozole
(Femara, and generics) for first-line treatment of
postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. It is the
first cyclin-dependent kinase inhibitor to become
available in the US.
Panobinostat (Farydak) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015 (Issue 1475)
prohibited.
For further information call: 800-211-2769
e119
The Medical Letter ® Vol. 57 (1475) August 17 ...
The FDA has approved panobinostat (Farydak –
Novartis), an oral histone deacetylase (HDAC) inhibitor,
for use in combination with bortezomib (Velcade) and
dexamethasone for treatment of patients with multiple
myeloma who have received at least 2 prior therapies
including bortezomib and an immunomodulatory
drug. It is the first HDAC inhibitor to be approved for
this indication.
Rifaximin (Xifaxan) for Irritable Bowel Syndrome with Diarrhea
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015 (Issue 1474)
.
110
The Medical Letter ® Vol. 57 (1474) August 3, 2015
Whether long-term use of rifaximin for IBS-D ...
Rifaximin (Xifaxan – Salix), a minimally absorbed
oral antibiotic approved previously to treat travelers'
diarrhea and to reduce the risk of recurrent hepatic
encephalopathy, has now been approved by the FDA
for treatment of irritable bowel syndrome with diarrhea
(IBS-D). Eluxadoline (Viberzi – Actavis), a mu-opioid
receptor agonist, was also recently approved for IBS-D
and will be reviewed in a future issue.
Sacubitril/Valsartan (Entresto) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015 (Issue 1474)
); 11.5 hrs (LBQ657)1;
9.9 hrs (valsartan)
1. Active metabolite of sacubitril.
The Medical Letter ® Vol ...
The FDA has approved Entresto (Novartis), an oral
fixed-dose combination of the neprilysin inhibitor
sacubitril and the angiotensin receptor blocker (ARB)
valsartan, to reduce the risk of cardiovascular death
and heart failure hospitalization in patients with
heart failure with reduced ejection fraction. Sacubitril
is the first neprilysin inhibitor to become available in
the US.
Polidocanol (Varithena) for Varicose Veins
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015 (Issue 1474)
The Medical Letter ® Vol. 57 (1474) August 3, 2015
CONCLUSION — Polidocanol injectable foam 1%
(Varithena ...
An injectable foam formulation of the sclerosing
agent polidocanol (Varithena – Provensis/BTG)
has been approved by the FDA for treatment of
incompetent veins and visible varicosities of the great
saphenous vein system. It is the first foam therapy to
be approved for this indication, but polidocanol and
other sclerosants have been used for years as foam
formulations compounded by physicians. Polidocanol
is also available in a liquid formulation (Asclera)
to treat smaller veins. Sodium tetradecyl sulfate
(Sotradecol) is FDA-approved in a liquid formulation
for use in...
Aptensio XR - Another Long-Acting Methylphenidate for ADHD
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015 (Issue 1473)
or to smooth withdrawal later in
the day.
102
The Medical Letter ® Vol. 57 (1473) July 20, 2015
ADVERSE ...
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both a rapid onset and a long duration of action. This formulation of methylphenidate has been available in Canada as Biphentin since 2006.
Namzaric - A Combination of 2 Old Drugs for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015 (Issue 1473)
The Medical Letter ® Vol. 57 (1473) July 20, 2015
decreased if it is administered with drugs ...
The FDA has approved Namzaric (Forest), a fixed-dose
combination of extended-release (ER)
memantine (Namenda XR), an NMDA-receptor
antagonist, and donepezil (Aricept, and generics),
an acetylcholinesterase inhibitor, for treatment of
moderate to severe Alzheimer's type dementia in
patients previously stabilized on both drugs. The
patent for Namenda has recently expired and generic
formulations of memantine 5- and 10-mg tablets have
been approved.
Prestalia - Another Combination for Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015 (Issue 1473)
in singleingredient
perindopril erbumine tablets (Aceon, and
generics).
105
The Medical Letter ® Vol. 57 (1473 ...
The FDA has approved Prestalia (Symplmed), an
oral fixed-dose combination of the dihydropyridine
calcium channel blocker amlodipine (Norvasc, and
generics) and a new salt form of the angiotensin-converting
enzyme (ACE) inhibitor perindopril, for
treatment of hypertension in patients not adequately
controlled on monotherapy or already taking both
drugs, and in those just starting therapy who are
likely to need multiple drugs to control their blood
pressure. The new salt form (perindopril arginine) is
more stable and has a longer shelf-life than perindopril
erbumine (Aceon, and...
Liletta - A Third Levonorgestrel-Releasing IUD
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015 (Issue 1472)
The Medical Letter ® Vol. 57 (1472) July 6, 2015
the hormone-free period of the previous method.
Patients ...
The FDA has approved Liletta, an intrauterine
device (IUD) that releases the synthetic progestin
levonorgestrel, for prevention of pregnancy for up to
3 years. The fourth IUD to be approved in the US, and
the third that releases levonorgestrel, Liletta is
comarketed by Actavis and Medicines360, a nonprofit
women's health pharmaceutical company. The wholesale
cost of Liletta is similar to that of other IUDs (see
Table 1), but the manufacturer offers programs that
significantly reduce the cost for commercially-insured
patients and clinics serving low-income women.